FDA Guidance Will Spur More Companion Diagnostic/Drug Trials – Nuvelo Exec
This article was originally published in The Gray Sheet
Unclear regulatory pathways for molecular diagnostic tests used to predict patients' response to particular drug therapies can impede the FDA approval process, Abbott Diagnostics Regulatory Affairs Director Matthew Klamrzynski maintained
You may also be interested in...
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.